Trump Accelerates Approval of Psychedelic Drugs for Mental Healthcare

• MDMA-assisted therapy showed 71% of severe PTSD patients no longer met diagnostic criteria in clinical trials, though the FDA rejected approval in 2024 citing study design concerns and need for additional data
• The executive order specifically mentions ibogaine, which has not undergone large-scale U.S. trials and carries serious cardiovascular risks, raising researcher concerns about standards being relaxed for political reasons
• Critics suggest the timing may be politically motivated to regain veteran support ahead of midterm elections, particularly as the administration pursues VA staffing cuts

Summary

President Donald Trump signed an executive order in April 2026 to accelerate psychedelic drug research for mental health treatment, marking a significant policy shift from his first administration's harder stance on controlled substances. The order granted priority review vouchers to three companies—Compass Pathways, Usona Institute, and Transcend Therapeutics—to expedite FDA review processes.

Key Market Reaction:

Psychedelic stocks rallied following the announcement, with Wall Street analysts viewing the order as legitimizing a previously fringe industry. Compass Pathways is nearing Phase 3 trials for its drug COMP360.

Clinical Evidence:

A study by the Multidisciplinary Association for Psychedelic Studies showed approximately 71% of severe PTSD participants no longer met diagnostic criteria after MDMA-assisted therapy. However, the FDA rejected MDMA-assisted therapy approval in 2024, citing study design concerns and insufficient data.

Compounds in Focus:

• MDMA: Primarily for PTSD treatment
• Psilocybin: Targeting depression
• Ibogaine: Under consideration for addiction and traumatic brain injuries, though carries high cardiovascular risks and lacks large-scale U.S. clinical trials

International Context:

Australia became the first country allowing authorized psychiatrists to prescribe MDMA and psilocybin for certain mental health conditions, with expanded clinical studies ongoing in Canada and the UK.

Concerns:

Researchers warn that political momentum may outpace scientific evidence. Safety concerns include panic attacks, paranoia, elevated heart rates, and the need for supervised therapeutic sessions with preparation and follow-up care. Critics question whether the timing relates to upcoming midterm elections and restoring veteran support amid VA staffing cuts.